Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Ikena Oncology, Inc. (IKNA : NSDQ)

• Company Description    Ikena Oncology Inc. is focused on developing cancer therapies targeting key signaling pathways which drive the formation and spread of cancer. The company's product candidates include IK-930, IK-175, IK-412 and IK-007, which are in clinical stage. Ikena Oncology Inc. is based in Boston, United States. Number of Employees: 67

• Price / Volume Information    Yesterday's Closing Price: $3.57 Daily Weekly Monthly 20 Day Moving Average: 234,712 shares Shares Outstanding: 36.11 (millions) Market Capitalization: $128.91 (millions) Beta: 1.26 52 Week High: $21.18 52 Week Low: $2.83 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -38.13% -30.32% 12 Week -49.22% -44.18% Year To Date -71.53% -63.95%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 645 SUMMER STREET SUITE 101 - BOSTON,MA 02210 USA ph: 857-273-8343 fax: - rcohen@ikenaoncology.com None

• General Corporate Information    Officers Mark Manfredi - Chief Executive Officer; President; Principal Fina Francisco Oliveira - Vice President of Finance and Administration Princ Ron Renaud - Director David Bonita - Director Iain D. Dukes - Director Peer Information Ikena Oncology, Inc. (CORR.) Ikena Oncology, Inc. (RSPI) Ikena Oncology, Inc. (CGXP) Ikena Oncology, Inc. (BGEN) Ikena Oncology, Inc. (GTBP) Ikena Oncology, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 45175G108 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/11/22 Share - Related Items Shares Outstanding: 36.11 Most Recent Split Date: (:1) Beta: 1.26 Market Capitalization: $128.91 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.46 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.83 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.67 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 81.35% vs. Previous Quarter: -771.43% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -83.26% ROE 03/31/22 - -20.11 12/31/21 - -15.96 09/30/21 - -46.12 ROA 03/31/22 - -16.23 12/31/21 - -12.61 09/30/21 - -25.12 Current Ratio 03/31/22 - 8.53 12/31/21 - 8.70 09/30/21 - 8.24 Quick Ratio 03/31/22 - 8.53 12/31/21 - 8.70 09/30/21 - 8.24 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - -150.79 12/31/21 - -110.10 09/30/21 - -1,652.14 Book Value 03/31/22 - 5.34 12/31/21 - 5.78 09/30/21 - 5.67 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©